CONSULTING AGREEMENT (Ulrich von Andrian)Consulting Agreement • March 30th, 2016 • Selecta Biosciences Inc • Pharmaceutical preparations • Massachusetts
This Consulting Agreement dated as of March 10, 2008 (this “Agreement”), is made by and between Selecta Biosciences, Inc., a Delaware corporation (the “Company”), and Ulrich von Andrian (the “Consultant”).
ContractSelecta Biosciences Inc • March 30th, 2016 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 30th, 2016 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
This Fifth Amended and Restated Investors’ Rights Agreement dated as of August 26, 2015 (this “Agreement”), is made by and among: (i) Selecta Biosciences, Inc., a Delaware corporation (the “Company”); (ii) the holders of the Company’s Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”), the Company’s Series D Convertible Preferred Stock, par value $0.0001 per share (the “Series D Preferred Stock”), the Company’s Series E Convertible Preferred Stock, par value $0.0001 per share, (the “Series E Preferred Stock” and, collectively with the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock and the Series D Preferred Stock, the “Senior Preferred Stock”), and the Company’s Series SRN
SELECTA BIOSCIENCES, INC. WARRANT TO PURCHASE COMMON STOCKPurchase Common Stock • March 30th, 2016 • Selecta Biosciences Inc • Pharmaceutical preparations • Massachusetts
This Warrant to Purchase Common Stock (this “Warrant”) is issued to or its registered assigns by Selecta Biosciences, Inc., a Delaware corporation (the “Company”). This Warrant is one of several like warrants (collectively, the “Warrants”) being issued in connection with the issuance by the Company to the holder (the “Holder”) of shares of the Company’s Series E Convertible Preferred Stock, $0.0001 par value per share, pursuant to that certain Series E Preferred Stock Purchase Agreement by and among the Company, the Holder and the other parties named therein, dated as of August 27, 2015 (the “Purchase Agreement”). By its acceptance hereof, the Holder hereby agrees to be bound by the terms and conditions of this Warrant.
ContractSelecta Biosciences Inc • March 30th, 2016 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
